Transactions
Since our inception in August 2016 we have advised corporate clients and raised more than SEK 11 billion from global specialist investors, blue chip pension funds and renown mutual funds. Before taking on a fund-raising advisory assignment we perform extensive due diligence to make sure that the companies we work with are of such high quality that we can leverage our global network of sophisticated investors. We take pride in executing transactions to help allocating capital to promising new life-saving efforts.
- Transactions
- 67
- Raised for clients
- SEK 11bn+
- Companies
- 24
- Advising since
- 2016
August 2026
SEK 40m
Rights issue
BiosergenPress release

June 2026
SEK 77m
Rights issue & directed issue
IRLAB TherapeuticsPress release
April 2026
SEK 113m
Rights issue & directed issue
SEK 83m + SEK 30m
Xspray PharmaPress release
April 2026
SEK 56m
Exercise of warrants
NanexaPress release
December 2025
SEK 71m
Rights issue & directed issue
SEK 42m + SEK 29m
BrainCoolPress release
December 2025
SEK 151m
Rights issue
MedivirPress release

October 2025
SEK 210m
Directed share & warrant issue
Intellego TechnologiesPress release
September 2025
SEK 150m
Rights issue
OncopeptidesPress release
September 2025
SEK 161m
Rights issue & directed issue
SEK 130m + SEK 31m
Xspray PharmaPress release
August 2025
SEK 32m
Rights issue
MenticePress release
August 2025
SEK 122m
Rights issue & directed issue
SEK 80m + SEK 42m
BiovicaPress release
July 2025
SEK 58m
Rights issue
AlzeCurePress release

July 2025
SEK 116m
Rights issue
IRLAB TherapeuticsPress release
June 2025
SEK 110m
Directed issue
SenzimePress release
January 2025
SEK 55m
Directed issue & loan
SEK 35m + SEK 20m
NanexaPress release
December 2024
SEK 120m
Rights issue
CantargiaPress release
December 2024
SEK 235m
Loan & rights issue
SEK 100m + SEK 135m
Xspray PharmaPress release

October 2024
SEK 100m
Directed issue
Vicore PharmaPress release

October 2024
SEK 782m
Rights issue
Vicore PharmaPress release
September 2024
SEK 86m
Directed issue
SenzimePress release
May 2024
SEK 39m
Rights issue
AlzeCurePress release
May 2024
SEK 86m
Rights issue
BrainCoolPress release
May 2024
SEK 314m
Rights issue
OncopeptidesPress release
April 2024
SEK 80m
Rights issue
LipumPress release
February 2024
SEK 33m
Directed issue
IconovoPress release
December 2023
SEK 129m
Rights issue
MedivirPress release
October 2023
SEK 59m
Directed issue
CantargiaPress release
October 2023
SEK 75m
Rights issue
NanexaPress release
September 2023
SEK 117m
Directed issue
SenzimePress release
September 2023
SEK 43m
Rights issue
ToleranziaPress release
August 2023
SEK 60m
Directed issue
BrainCoolPress release
August 2023
SEK 56m
Directed issue
SenzimePress release
June 2023
SEK 251m
Rights issue
Xspray PharmaPress release

June 2023
SEK 500m
Directed issue
Vicore PharmaPress release
December 2022
SEK 31m
Directed issue
BrainCoolPress release

December 2022
SEK 200m
Directed issue
Vicore PharmaPress release
November 2022
SEK 82m
Rights issue
BrainCoolPress release
October 2022
SEK 100m
Directed issue
Xspray PharmaPress release

October 2022
SEK 50m
Rights issue
Qlife HoldingPress release

October 2022
SEK 80m
Rights issue
NanologicaPress release

October 2021
SEK 159m
Directed issue
Episurf MedicalPress release

April 2021
SEK 90m
Directed issue
Qlife HoldingPress release

February 2021
SEK 336m
Directed issue
Vicore PharmaPress release

December 2020
SEK 130m
Directed issue
IRLAB TherapeuticsPress release

November 2020
SEK 66m
Directed issue
Episurf MedicalPress release
October 2020
SEK 265m
Directed issue
Xspray PharmaPress release

July 2020
SEK 1,112m
Directed issue
Hansa BiopharmaPress release

July 2020
SEK 185m
Directed issue
Vicore PharmaPress release
February 2020
SEK 410m
Directed issue
CantargiaPress release

February 2020
SEK 140m
Directed issue & rights issue
Episurf MedicalPress release

December 2019
SEK 215m
Directed issue & rights issue
IRLAB TherapeuticsPress release
December 2019
SEK 122m
Directed issue
Xspray PharmaPress release

November 2019
SEK 125m
Directed issue
Vicore PharmaPress release

October 2019
SEK 48m
Directed issue
Asarina PharmaPress release
July 2019
SEK 300m
Directed issue & secondary sale
Calliditas TherapeuticsPress release
December 2018
SEK 92m
Directed issue
Xspray PharmaPress release

November 2018
SEK 160m
Directed issue
Vicore PharmaPress release

November 2018
SEK 675m
Directed issue & secondary sale
Hansa BiopharmaPress release

September 2018
SEK 150m
IPO
Asarina PharmaPress release

June 2018
M&A
Vicore PharmaPress release

May 2018
SEK 139m
Directed issue
IRLAB TherapeuticsPress release
January 2018
SEK 88m
Directed issue
Xspray PharmaPress release

November 2017
SEK 545m
Directed issue
Hansa BiopharmaPress release
November 2017
SEK 545m
Directed issue & rights issue
Infant Bacterial TherapeuticsPress release
August 2017
SEK 132m
IPO
Xspray PharmaPress release

February 2017
SEK 56m
Directed issue
Vicore PharmaPress release

November 2016
SEK 185m
Directed issue
Hansa BiopharmaPress release